Citation Impact
Citing Papers
PPAR-Induced Fatty Acid Oxidation in T Cells Increases the Number of Tumor-Reactive CD8+ T Cells and Facilitates Anti–PD-1 Therapy
2018 StandoutNobel
Genome-wide CRISPR screens reveal a specific ligand for the glycan-binding immune checkpoint receptor Siglec-7
2021 StandoutNobel
Trained immunity: A program of innate immune memory in health and disease
2016 StandoutScience
Crippling life support for SARS-CoV-2 and other viruses through synthetic lethality
2020 StandoutNobel
PD-1 + regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer
2019 StandoutNobel
PARP inhibitors: Synthetic lethality in the clinic
2017 StandoutScience
PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
2017 StandoutNature
Targeted glycan degradation potentiates the anticancer immune response in vivo
2020 StandoutNobel
T cell exhaustion: from pathophysiological basics to tumor immunotherapy
2017
Satb1 regulates the effector program of encephalitogenic tissue Th17 cells in chronic inflammation
2019 StandoutNobel
Reading the glyco-code: New approaches to studying protein–carbohydrate interactions
2022 StandoutNobel
HIF-independent synthetic lethality between CDK4/6 inhibition and VHL loss across species
2019 StandoutNobel
The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications
2020 Standout
Dendritic cells in cancer immunology and immunotherapy
2019 Standout
Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy
2019
Elements of cancer immunity and the cancer–immune set point
2017 StandoutNature
VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer
2017 StandoutNobel
Immune Checkpoints as Therapeutic Targets in Autoimmunity
2018
Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family
2016
Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes
2018 StandoutNobel
Inflammation and tumor progression: signaling pathways and targeted intervention
2021 Standout
Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy
2015
Th1 cytokine-based immunotherapy for cancer
2014
The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans
2021 StandoutNobel
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
2017 Standout
The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth
2023 Standout
Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy
2017 Standout
Coinhibitory Receptor Expression and Immune Checkpoint Blockade: Maintaining a Balance in CD8+ T Cell Responses to Chronic Viral Infections and Cancer
2017 StandoutNobel
PGE2-EP2/EP4 signaling elicits immunosuppression by driving the mregDC-Treg axis in inflammatory tumor microenvironment
2022 StandoutNobel
Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy
2017 Standout
Defining trained immunity and its role in health and disease
2020 Standout
The mechanism of action of BCG therapy for bladder cancer—a current perspective
2014
A guide to cancer immunotherapy: from T cell basic science to clinical practice
2020 Standout
Computational design of a synthetic PD-1 agonist
2021 StandoutNobel
Diversity, Mechanisms, and Significance of Macrophage Plasticity
2019 Standout
VISTA Is a Novel Broad-Spectrum Negative Checkpoint Regulator for Cancer Immunotherapy
2014
Nanotechnology for Multimodal Synergistic Cancer Therapy
2017 Standout
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
2018 StandoutNobel
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
2016 Standout
Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses
2015
Combination therapy strategies for improving PD‐1 blockade efficacy: a new era in cancer immunotherapy
2017 StandoutNobel
Combining Immune Checkpoint Inhibitors and Kinase-Inhibiting Supramolecular Therapeutics for Enhanced Anticancer Efficacy
2016
Disruption of the immune-checkpoint VISTA gene imparts a proinflammatory phenotype with predisposition to the development of autoimmunity
2014
New checkpoints in cancer immunotherapy
2017
Mitochondrial activation chemicals synergize with surface receptor PD-1 blockade for T cell-dependent antitumor activity
2017 StandoutNobel
Works of Tomoe Higuchi being referenced
CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer
2015
A possible mechanism of intravesical BCG therapy for human bladder carcinoma: involvement of innate effector cells for the inhibition of tumor growth
2009
Coinhibitory receptor PD-1H preferentially suppresses CD4+ T cell–mediated immunity
2014
Mechanistic Assessment of PD-1H Coinhibitory Receptor–Induced T Cell Tolerance to Allogeneic Antigens
2015